

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

HARBOUR
B I O M E D
和 鉑 醫 藥 控 股 有 限 公 司

HBM Holdings Limited

(incorporated in the Cayman Islands with limited liability)

(Stock Code: 02142)

VOLUNTARY ANNOUNCEMENT
APPROVAL OF INVESTIGATIONAL NEW DRUG
APPLICATION FOR HBM7575 FOR ASTHMA BY THE NMPA

This announcement is made by HBM Holdings Limited (the “**Company**”, together with its subsidiaries, the “**Group**”) on a voluntary basis to inform the shareholders and potential investors of the Company about the latest business update of the Group.

The board of directors of the Company (the “**Board**”) is pleased to announce that the Investigational New Drug (“**IND**”) application for HBM7575 (also known as SKB575), a long-acting bispecific antibody targeting thymic stromal lymphopoietin (“**TSLP**”) and an undisclosed target for the treatment of asthma, has been approved by the National Medical Products Administration of China (the “**NMPA**”). This bispecific antibody was co-developed by Harbour BioMed and Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. (“**Kelun-Biotech**”) (6990.HK). Previously, the first participant has been dosed for the Phase I clinical study of HBM7575/SKB575 for the treatment of atopic dermatitis.

About HBM7575/SKB575

HBM7575/SKB575 is a long-acting bispecific antibody targeting TSLP and an undisclosed antigen, with a dual mechanism of action. On one hand, by blocking the interaction between TSLP and its receptor, it inhibits TSLP-mediated signaling pathways and the activation of Th2 immune cells. On the other hand, binding to and blocking the undisclosed target generates a synergistic effect, with the potential to achieve broader control of inflammation compared to single-target approaches. HBM7575/SKB575 has been engineered to allow for longer dosing intervals and a convenient subcutaneous route of administration. Based on preclinical half-life data, the anticipated human half-life is expected to support dosing intervals of more than three months, positioning it as a potential best-in-class therapy.

According to the collaboration agreement between the Company and Kelun-Biotech, HBM7575/SKB575 is led by Kelun-Biotech in its design, global development and commercialization, with the Company participating in the investment and development of this asset and sharing the benefits as agreed.

Cautionary Statement: We cannot guarantee that we or our collaboration partner will be able to successfully develop or ultimately market HBM7575/SKB575. Shareholders and potential investors of the Company are advised to exercise due care when dealing in the shares of the Company.

By order of the Board
HBM Holdings Limited
Dr. Jingsong Wang
Chairman and Executive Director

Hong Kong, 15 July 2026

As at the date of this announcement, the Board comprises Dr. Jingsong Wang and Dr. Yiping Rong as executive Directors; Dr. Robert Irwin Kamen, Dr. Xiaoping Ye, Dr. Albert R. Collinson and Ms. Weiwei Chen as independent non-executive Directors.